Sanofi Deepens Mirecule And Earendil Ties To Shape Rare Disease Future [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
Sanofi (ENXTPA:SAN) has expanded its rare disease collaboration with Mirecule, focusing on next generation treatments for neuromuscular conditions. The company has deepened its relationship with Earendil Labs through a large investment and repeated partnerships in AI driven biologics discovery. These moves highlight a broader shift in Sanofi's external innovation approach beyond its previously discussed venglustat milestone. Sanofi, a global biopharma group with a long track record in rare diseases and immunology, is placing more weight on external partnerships to source new therapies. The expanded Mirecule collaboration keeps rare neuromuscular diseases at the center of its specialty care focus, while Earendil Labs gives Sanofi access to AI tools for biologics that many large pharma peers are also exploring. For investors in ENXTPA:SAN, these agreements help clarify where the company is looking for future product opportunities. Looking ahead, Sanofi's deeper ties with Mirecu
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Sanofi (SNY) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "hold (c-)" to "sell (d+)".MarketBeat
- Sanofi Autoimmune Pipeline Grows As Market Weighs Valuation And Momentum [Yahoo! Finance]Yahoo! Finance
- Kali and Sanofi sign licence agreement for KT501 autoimmune disease antibody [Yahoo! Finance]Yahoo! Finance
- Press release: Availability of the Q1 2026 aide-mémoire [Yahoo! Finance]Yahoo! Finance
- Press release: Availability of the Q1 2026 aide-mémoireGlobeNewswire
SNY
Sec Filings
- 3/24/26 - Form 6-K
- 3/10/26 - Form 6-K
- 3/4/26 - Form 6-K
- SNY's page on the SEC website